Skip to main content

Marc Miravitlles Fernández

I’m a specialist in Respiratory Medicine trained at Vall d’Hebron Hospital in Barcelona. My focus is on clinical research in chronic obstructive pulmonary disease (COPD) and alpha-1 antitrypsin deficiency (AATD) with the objective to find a cure and improve the quality of life of patients suffering these chronic respiratory diseases.

Institutions of which they are part

Main researcher
Pneumology
Vall Hebron Institut de Recerca
Doctor
Pneumology
General Hospital

Marc Miravitlles Fernández

Institutions of which they are part

Main researcher
Pneumology
Vall Hebron Institut de Recerca
Doctor
Pneumology
General Hospital

I’m a specialist in Respiratory Medicine trained at Vall d’Hebron Hospital in Barcelona. My focus is on clinical research in chronic obstructive pulmonary disease (COPD) and alpha-1 antitrypsin deficiency (AATD) with the objective to find a cure and improve the quality of life of patients suffering these chronic respiratory diseases.

I’m a Pulmonologist and Senior Researcher at the Vall d’Hebron University Hospital and the Vall d’Hebron Research Institute (VHIR) in Barcelona, Spain.
I obtained my MD at the Universitat de Barcelona, Barcelona, Spain in 1986 and my PhD at the Universitat Autònoma de Bacelona in 1997. I trained as specialist in Respiratory Medicine at Vall d'Hebron Hospital. My primary research interests include chronic obstructive pulmonary disease (COPD), alpha-1-antitrypsin deficiency (AAT), lung defence mechanisms and respiratory infections. I served as Secretary General of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) from 1999 to 2003 and I was responsible for International Relationships of SEPAR from 2006 until 2012. I was Chair of the Respiratory Infections Group of the European Respiratory Society (ERS) from 2008 to 2011 and I was the Guidelines Director of the ERS from 2015 to 2018.
I have acted as a consultant and/or chair or author for the development of different international guidelines of COPD, including the American Thoracic Society (ATS)/ERS task force on outcomes in COPD, the ERS/ATS guidelines on diagnostic and treatment of exacerbations of COPD and the ERS statement on management of alpha-1 antitrypsin deficiency. I am also a consultant of the Spanish Ministry of Health for the development of the National Strategy Against COPD (2009 to present) and coordinator of the Spanish National Guidelines for COPD (GesEPOC from 2012). I am the director of the reference center for diagnosis and treatment of AATD in the Hospital Vall d’Hebron and I am author of 498 publications listed in PubMed and a h-index of 73 (May 2020)

Related news

The event brought together experts from the Vall d’Hebron Institute of Research (VHIR) and the Institute of Geosciences of Barcelona to analyze how environmental factors and the climate crisis impact population health.

The grants, amounting to more than €533,000 for VHIR, will allow clinical duties to be partially released over three years to promote strategic research projects in obesity, respiratory diseases, aortic pathology and metabolic fatty liver disease.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

Related professionals

Anna Enrich  Font

Anna Enrich Font

Research technician
Clinical Research/Innovation in Pneumonia & Sepsis (CRIPS)
Read more
Ernesto Melchor Guerra Farfan

Ernesto Melchor Guerra Farfan

Main researcher
Reconstructive Surgery of the Locomotor System
Read more
Sara Delgado Tomás

Sara Delgado Tomás

Postdoctoral researcher
Cardiovascular Diseases
Read more
Carmen Llorens Cebriá

Carmen Llorens Cebriá

Tècnic de recerca
Internal Strategy Directorate
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.